You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 23, 2024

Claims for Patent: 9,649,383

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,649,383

Title:	Liquid formulations for TNFR:Fc fusion proteins
Abstract:	The invention provides stable liquid formulations for a recombinant biopharmaceutical protein comprising a soluble form of the human p75 TNF receptor fused to an Fe domain of a human immunoglobulin protein (TNFR:Fc). Typically, biopharmaceutical proteins such as monoclonal antibodies (mAbs) and immunoglobulin fusion proteins (e.g., immunoadhesion proteins) are produced by recombinant DNA technology in mammalian cell expression systems. In order to guarantee the reproducible clinical performance of a biopharmaceutical product, manufacturers have to deliver a product of consistent and reproducible quality.
Inventor(s):	Kashi; Ramesh S. (Warren, NJ), Patel; Shona P. (Florham Park, NJ), Mittal; Sarita (Bridgewater, NJ), Basarkar; Ashwin (Springfield, NJ), Shi; Shuai (Summit, NJ)
Assignee:	Merck Sharp & Dohme Corp. (Rahway, NJ)
Application Number:	14/443,557
Patent Claims:	1. A stable liquid pharmaceutical formulation comprising 50 mg/ml etanercept, a citrate-phosphate buffer, 100 or 125 mM sodium chloride, L-histidine, and sucrose, pH 6.0-6.5. 2. The formulation of claim 1, wherein the amino acid is L-histidine at a concentration of 25 mM. 3. The formulation of claim 2, wherein the sugar is present at a concentration of about 1%. 4. The formulation of claim 1, comprising 50 mg/ml etanercept, a 25 mM citrate-phosphate buffer pH 6.3, 100 mM sodium chloride, 25 mM L-histidine and 1% sucrose. 5. The formulation of claim 1 wherein etanercept exhibits stability over at least about 12 months.

Details for Patent 9,649,383

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Immunex Corporation	ENBREL	etanercept	For Injection	103795	11/02/1998	⤷ Try a Trial	2039-02-26
Immunex Corporation	ENBREL	etanercept	For Injection	103795	05/27/1999	⤷ Try a Trial	2039-02-26
Immunex Corporation	ENBREL	etanercept	Injection	103795	09/27/2004	⤷ Try a Trial	2039-02-26
Immunex Corporation	ENBREL	etanercept	Injection	103795	02/01/2007	⤷ Try a Trial	2039-02-26
Immunex Corporation	ENBREL MINI	etanercept	Injection	103795	09/14/2017	⤷ Try a Trial	2039-02-26
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.